Full Text View
Tabular View
No Study Results Posted
Related Studies
EPO906 in Carcinoid and Other Neuroendocrine Tumors
This study has been suspended.
Study NCT00050349   Information provided by Novartis
First Received: December 4, 2002   Last Updated: September 18, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoid
Neuroendocrine Tumors
Additional conditions recognized in this trial
Carcinoid Tumor
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Interventions listed in this trial
EPO906 epothilone B
Additional drug interventions recognized in this trial
Epothilone B
Epothilones
More general drug interventions related to this trial
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services